Myriad Genetics Stock
Myriad Genetics Stock
Myriad Genetics shows a slight decrease today, losing -€0.200 (-0.850%) compared to yesterday.
Based on 4 Buy predictions and 3 Sell predictions the sentiment towards Myriad Genetics is rather balanced.
On the other hand, the target price of 22 € is below the current price of 23.2 € for Myriad Genetics, so the potential is actually -5.17%.
Pros and Cons of Myriad Genetics in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Myriad Genetics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Myriad Genetics | -0.850% | -7.813% | -4.839% | 53.247% | 33.333% | -19.810% | -13.124% |
| Integer Hldg | -0.880% | 0.893% | 0.893% | 54.795% | 26.966% | 47.712% | 62.543% |
| Healthequity Inc. | 0.720% | 0.719% | 2.941% | 2.941% | 17.647% | 24.600% | 32.601% |
| Omnicell Inc. | -0.530% | -4.000% | -4.000% | -17.949% | 9.714% | -70.687% | -41.356% |
Comments
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at JPMorgan Chase & Co. from $17.00 to $20.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its "underperform" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $20.00 price target on the stock, down previously from $25.00.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $35.00 price target on the stock, up previously from $25.00.
Show more
Ratings data for MYGN provided by MarketBeat